Want to see JP:4890 full AI Analyst Report?

Tsubota Laboratory Incorporated (4890) Price & Analysis

1 Followers

4890 Stock Chart & Stats

¥340.00

¥1.00(0.24%)

At close: Jan 08 4:00 PM EST

¥340.00

¥1.00(0.24%)

Day’s Range― - ―

52-Week Range¥210.00 - ¥478.00

Previous CloseN/A

Volume43.10K

Average Volume (3M)33.61K

Market Cap

¥6.57B

Enterprise Value¥5.27B

Total Cash (Recent Filing)¥699.26M

Total Debt (Recent Filing)¥63.64M

Price to Earnings (P/E)―

Beta0.26

Next Earnings

Nov 11, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-26.90

Shares Outstanding25,969,738

10 Day Avg. Volume26,960

30 Day Avg. Volume33,606

Financial Highlights & Ratios

PEG Ratio0.02

Price to Book (P/B)8.77

Price to Sales (P/S)37.86

P/FCF Ratio-12.91

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Conservative Balance SheetLow leverage and substantial equity provide a meaningful capital cushion while operations fluctuate. This reduces balance-sheet pressure and preserves financial flexibility to fund ophthalmology development or absorb continued earnings volatility over the next several quarters.

Strong Gross MarginA gross margin near 66% indicates that the company’s offerings retain substantial value after direct costs. If revenue stabilizes, this margin profile could support operating recovery because incremental sales may contribute meaningfully toward covering the fixed cost base.

Demonstrated Prior ProfitabilityPrior profitable years and the 2025 rebound show that the business has previously converted its ophthalmology activities into operating and net earnings. That history provides evidence of potential earnings capacity, even though the latest year shows substantial deterioration.

Bears Say

Severe Revenue ContractionThe sharp revenue contraction signals a major deterioration in demand, commercialization, or operating scale. Such a drop can weaken market presence, reduce cost absorption, and make recovery dependent on rebuilding sales rather than simply improving efficiency.

Deep Operating LossesExtremely negative profitability means current revenue is insufficient to support the company’s cost structure. Persistent losses can erode equity, constrain investment in ophthalmology products, and make future performance highly sensitive to the timing and scale of any revenue recovery.

Persistent Cash BurnRepeated negative operating and free cash flow shows that reported activities are not currently funding the business internally. Continued cash burn may create ongoing funding needs and reduce financial flexibility, even though leverage remains comparatively low.

Tsubota Laboratory Incorporated News

Tsubota Laboratory Narrows Quarterly Loss as Revenue Surges and Eyes Full-Year Profit

Tsubota Laboratory Incorporated ( ($JP:4890) ) has issued an announcement. Tsubota Laboratory reported a sharp increase in first-quarter...

3M ago

4890

Tsubota Lab Emphasizes ‘VISIONary INNOVATION’ in Vision and Brain Health

Tsubota Laboratory Incorporated ( ($JP:4890) ) has shared an update. Tsubota Lab Co., an R&D-based venture from Keio...

5M ago

4890

Tsubota Laboratory Swings to Loss but Projects Sharp Rebound in 2027

Tsubota Laboratory Incorporated ( ($JP:4890) ) has shared an update. Tsubota Laboratory reported a sharp downturn in non-consolidated...

6M ago

4890

Tsubota Laboratory Swings to Heavy Loss as Revenue Plunges, Forecasts Deep Full-Year Deficit

Tsubota Laboratory Incorporated ( ($JP:4890) ) has shared an update. Tsubota Laboratory reported a sharp deterioration in non-consolidated...

9M ago

4890

Tsubota Laboratory’s Interim Financial Results Highlight Sustainable Growth Strategy

Tsubota Laboratory Incorporated ( ($JP:4890) ) has provided an announcement. Tsubota Laboratory Incorporated has announced its interim financial...

11M ago

4890

Tsubota Laboratory Reports Significant Revenue Decline and Net Loss

Tsubota Laboratory Incorporated ( ($JP:4890) ) has shared an update. Tsubota Laboratory Incorporated reported a significant decline in...

12M ago

4890

Tsubota Laboratory Reports First Quarter Losses Amidst Sales Decline

An update from Tsubota Laboratory Incorporated ( ($JP:4890) ) is now available. Tsubota Laboratory Incorporated reported a decrease...

1y ago

4890

Tsubota Laboratory Reports Strong Financial Recovery in FY2025

The latest announcement is out from Tsubota Laboratory Incorporated ( ($JP:4890) ). Tsubota Laboratory, Inc. reported significant financial...

1y ago

4890

4890 FAQ

What was Tsubota Laboratory Incorporated’s price range in the past 12 months?

Tsubota Laboratory Incorporated lowest stock price was ¥210.00 and its highest was ¥478.00 in the past 12 months.

What is Tsubota Laboratory Incorporated’s market cap?

Tsubota Laboratory Incorporated’s market cap is ¥6.57B.

When is Tsubota Laboratory Incorporated’s upcoming earnings report date?

Tsubota Laboratory Incorporated’s upcoming earnings report date is Nov 11, 2026 which is in 13 days.

How were Tsubota Laboratory Incorporated’s earnings last quarter?

Tsubota Laboratory Incorporated released its earnings results on Aug 12, 2026. The company reported -¥5.2 earnings per share for the quarter.

Is Tsubota Laboratory Incorporated overvalued?

According to Wall Street analysts Tsubota Laboratory Incorporated’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Tsubota Laboratory Incorporated pay dividends?

Tsubota Laboratory Incorporated does not currently pay dividends.

What is Tsubota Laboratory Incorporated’s EPS estimate?

Tsubota Laboratory Incorporated’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Tsubota Laboratory Incorporated have?

Tsubota Laboratory Incorporated has 25,969,738 shares outstanding.

What happened to Tsubota Laboratory Incorporated’s price movement after its last earnings report?

Tsubota Laboratory Incorporated reported an EPS of -¥5.2 in its last earnings report. Following the earnings report the stock price went up 2.23%.

Which hedge fund is a major shareholder of Tsubota Laboratory Incorporated?

Currently, no hedge funds are holding shares in JP:4890

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Tsubota Laboratory Incorporated

Operating from Tokyo, Japan since its establishment in 2012, Tsubota Laboratory Incorporated is dedicated to the research and development of pharmaceutical products and medical devices, specifically targeting the treatment of myopia, dry eyes, and presbyopia.